Volume : 10, Issue : 02, February – 2023
Title:
20.NEUROLEPTIC MALIGNANT SYNDROME: A REVIEW
Authors :
A R Shabaraya and M V Prathvi*
Abstract :
Neuroleptic malignant syndrome (NMS) is a rare but potentially fatal complication associated with the use of neuroleptic drugs. It is a life-threatening neurologic emergency associated with the use of dopamine antagonists, and less commonly with dopamine agonist withdrawal. It occurs with 0.2 % of patients with neuroleptics. First-generation antipsychotic agents are most commonly implicated, but NMS can occur with any antipsychotic agent and also with antiemetic drugs. It presents with the tetrad of clinical features hyperthermia, muscle rigidity, mental status changes, and autonomic dysfunction. Risk factors of NMS include Previous episodes, dehydration, agitation, and the rate and route of neuroleptic administration. Patients with psychiatric illness or mood disorders, especially those on lithium, may be at higher risk for NMS despite the fact that it has been reported in patients with diverse psychiatric diagnoses as well as in normal patients. Important considerations in the differential diagnosis include meningitis, encephalitis, systemic infections, heat stroke, and other drug-induced dysautonomias. The syndrome lasts for 7 to 10 days in uncomplicated cases receiving oral neuroleptics. The treatment mainly consists of early recognition, discontinuation of triggering drugs, management of fluid balance, temperature reduction, and monitoring for complications. Use of dopamine agonists (eg. bromocriptine, amantadine) or dantrolene or both should be considered in treating in more severe, prolonged, or refractory cases. Electroconvulsive therapy (ECT) is an option in patients not responding to drug treatment in the first week, those with residual catatonia persists after other symptoms have resolved, and those in whom lethal catatonia is suspected as an alternative or concomitant disorder. it has been used successfully in the post-NMS patients. As a result of these measures, mortality from NMS has reduced in recent years although fatalities still occur. In the majority of patients who have recovered from an NMS episode, neuroleptics may be safely reintroduced. The lack of knowledge regarding NMS may delay the onset of therapy, impair the quality of treatment, and lead to a worse outcome or even cause death.
KEYWORDS: Neuroleptic Malignant Syndrome, Dopamine antagonist, Hyperthermia, Dantrolene, Electroconvulsive therapy
Cite This Article:
Please cite this article in press M V Prathvi et al, Neuroleptic Malignant Syndrome: A Review., Indo Am. J. P. Sci, 2023; 10 (02).
Number of Downloads : 10
References:
2. Velamoor VR, Norman RM, Caroff SN, et al. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis 1994; 168-82.
3. Picard LS, Lindsay S, Strawn JR, et al. Atypical neuroleptic malignant syndrome: diagnostic controversies and considerations. Pharmacotherapy 2008; 530-45.
4. Strawn JR, Keck Jr, MD PE, Caroff SN. Neuroleptic malignant syndrome. American Journal of Psychiatry. 2007 Jun;164(6):870-6
5. Caroff SN, Mann SC. Neuroleptic malignant syndrome. The Medical clinics of North America. 1993 Jan 1;77(1):185-202.
6. Adnet P, Lestavel P, Krivosic‐Horber R. Neuroleptic malignant syndrome. British journal of anaesthesia. 2000 Jul 1;85(1):129-35.
7. Chandran GJ, Mikler JR, Keegan DL. Neuroleptic malignant syndrome: case report and discussion. Cmaj. 2003 Sep 2;169(5):439-42.
8. Shalev A, Hermesh H, Munitz H. Mortality from neuroleptic malignant syndrome. The Journal of clinical psychiatry. 1989 Jan.
9. Adnet P, Lestavel P, Krivosic-Horber R. Neuroleptic malignant syndrome. Br J Anaesth 2000; 129-46.
10. Rosebush P, Stewart T. A prospective analysis of 24 episodes of neuroleptic malignant syndrome. Am J Psychiatry 1989; 717-56.
11. Adityanjee . The myth of elevated serum creatine phosphokinase level and neuroleptic malignant syndrome. Br J Psychiatry 1991; 706-23.
12. Hermesh H, Manor I, Shiloh R, et al. High serum creatinine kinase level: possible risk factor for neuroleptic malignant syndrome. J Clin Psychopharmacol 2002; 252-68.
13. Carbone JR. The neuroleptic malignant and serotonin syndromes. Emerg Med Clin North Am 2000; 317-18.
14. Hasan S, Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Am J Psychiatry 1998; 155-1113.
15. Blasi C, D’Amore F, Levati M, Bandinelli MC. [Neuroleptic malignant syndrome: a neurologic pathology of great interest for the internist]. Ann Ital Med Int 1998; 111-13.
16. Lyons JL, Cohen AB. Selective cerebellar and basal ganglia injury in neuroleptic malignant syndrome. J Neuroimaging 2013; 240-55.
17. Caroff SN, Rosenberg H, Fletcher JE, et al. Malignant hyperthermia susceptibility in neuroleptic malignant syndrome. Anesthesiology 1987; 20-67.
18. Bodner RA, Lynch T, Lewis L, Kahn D. Serotonin syndrome. Neurology 1995; 219-45.
19. Ener RA, Meglathery SB, Van Decker WA, Gallagher RM. Serotonin syndrome and other serotonergic disorders. Pain Med 2003; 63-4.
20. Lejoyeux M, Fineyre F, Adès J. The serotonin syndrome. Am J Psychiatry 1992; 149-52
21. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148-705.
22. Werneke U, Jamshidi F, Taylor DM, Ott M. Conundrums in neurology: diagnosing serotonin syndrome – a meta-analysis of cases. BMC Neurol 2016; 16-97.
23. Fleischhacker WW, Unterweger B, Kane JM, Hinterhuber H. The neuroleptic malignant syndrome and its differentiation from lethal catatonia. Acta Psychiatr Scand 1990; 3-81.
24. Castillo E, Rubin RT, Holsboer-Trachsler E. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am J Psychiatry 1989; 146-324.
25. Coffey RJ, Edgar TS, Francisco GE, et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil 2002; 83-735.
26. Prevention and treatment of heat injury. Med Lett Drugs Ther 2003; 45-58.
27. Parry AK, Ormerod LP, Hamlin GW, Saleem PT. Recurrent sinus arrest in association with neuroleptic malignant syndrome. Br J Psychiatry 1994; 164-689.
28. Guzé BH, Baxter LR Jr. Current concepts. Neuroleptic malignant syndrome. N Engl J Med 1985; 163-73.
29. Lappa A, Podestà M, Capelli O, et al. Successful treatment of a complicated case of neuroleptic malignant syndrome. Intensive Care Med 2002; 976-88.
30. Gregorakos L, Thomaides T, Stratouli S, Sakayanni E. The use of clonidine in the management of autonomic overactivity in neuroleptic malignant syndrome. Clin Auton Res 2000; 193-210.
31. Blue MG, Schneider SM, Noro S, Fraley DS. Successful treatment of neuroleptic malignant syndrome with sodium nitroprusside. Ann Intern Med 1986; 104-56.
32. Reulbach U, Dütsch C, Biermann T, et al. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care 2007; 11-R4.
33. Bond WS. Detection and management of the neuroleptic malignant syndrome. Clin Pharm 1984; 302-03.
34. Tsutsumi Y, Yamamoto K, Matsuura S, et al. The treatment of neuroleptic malignant syndrome using dantrolene sodium. Psychiatry Clin Neurosci 1998; 433-52.
35. Bhanushali MJ, Tuite PJ. The evaluation and management of patients with neuroleptic malignant syndrome. Neurol Clin 2004; 389-92.
36. Wilkinson R, Meythaler JM, Guin-Renfroe S. Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury. Brain Inj 1999; 1025-38.
37. Kontaxakis VP, Vaidakis NM, Christodoulou GN, Valergaki HC. Neuroleptic-induced catatonia or a mild form of neuroleptic malignant syndrome? Neuropsychobiology 1990; 23-38.
38. Trollor JN, Sachdev PS. Electroconvulsive treatment of neuroleptic malignant syndrome: a review and report of cases. Aust N Z J Psychiatry 1999; 33:650.
39. Morcos N, Rosinski A, Maixner DF. Electroconvulsive Therapy for Neuroleptic Malignant Syndrome: A Case Series. J ECT 2019.
40. Rajan R, Sage M. Successful Emergency Treatment of Refractory Neuroleptic Malignant Syndrome With Electroconvulsive Therapy and a Novel Use of Dexmedetomidine: A Case Report From California in the Era of COVID-19. J ECT 2021; 37-71.
41. Rosenberg MR, Green M. Neuroleptic malignant syndrome. Review of response to therapy. Arch Intern Med 1989; 1927-9.
42. Rosebush PI, Stewart T, Mazurek MF. The treatment of neuroleptic malignant syndrome. Are dantrolene and bromocriptine useful adjuncts to supportive care? Br J Psychiatry 1991; 709-59.
43. Foguet-Boreu Q, Coll-Negre M, Serra-Millàs M, Cavalleria-Verdaguer M. Neuroleptic malignant syndrome: a case responding to electroconvulsive therapy plus bupropion. Clin Pract 2018; 1044-8.
44. Yang CJ, Chiu CT, Yeh YC, Chao A. Successful management of delirium with dexmedetomidine in a patient with haloperidol-induced neuroleptic malignant syndrome: A case report. World J Clin Cases 2022; 625-30.
45. Bienvenu OJ, Neufeld KJ, Needham DM. Treatment of four psychiatric emergencies in the intensive care unit. Crit Care Med 2012; 2662-80.
46. Harris M, Nora L, Tanner CM. Neuroleptic malignant syndrome responsive to carbidopa/levodopa: support for a dopaminergic pathogenesis. Clin Neuropharmacol 1987; 186-90.
47. Wang HC, Hsieh Y. Treatment of neuroleptic malignant syndrome with subcutaneous apomorphine monotherapy. Mov Disord 2001; 16:765.
48. Thomas P, Maron M, Rascle C, et al. Carbamazepine in the treatment of neuroleptic malignant syndrome. Biol Psychiatry 1998; 303-43.